Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

362 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 362 results

Testing effectiveness (Phase 2)Study completedNCT01051596
What this trial is testing

ABT-888 in Combination With Temozolomide for Colorectal Cancer

Who this might be right for
Colorectal Cancer
Georgetown University 75
Early research (Phase 1)Study completedNCT02044120
What this trial is testing

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Who this might be right for
Ewing Sarcoma
Sarcoma Alliance for Research through Collaboration 34
Testing effectiveness (Phase 2)Study completedNCT01989546
What this trial is testing

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Who this might be right for
Advanced Ovarian CancerPrimary Peritoneal CancerAdvanced Breast Cancer+1 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)UnknownNCT05392686
What this trial is testing

PD1 and PARP for Maintenance Therapy in NSLLC

Who this might be right for
Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 52
Early research (Phase 1)Study completedNCT04335604
What this trial is testing

NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Onconic Therapeutics Inc. 62
Early research (Phase 1)WithdrawnNCT03575078
What this trial is testing

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Who this might be right for
Lymphoma
University of Texas Southwestern Medical Center
Early research (Phase 1)Study completedNCT03343054
What this trial is testing

Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Who this might be right for
NeoplasmsBreast Neoplasms
Pfizer 28
Early research (Phase 1)Study completedNCT04703920
What this trial is testing

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Who this might be right for
Metastatic Breast CancerMetastatic Castration-resistant Prostate CancerMetastatic Ovarian Carcinoma+1 more
University of Michigan Rogel Cancer Center 26
Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Testing effectiveness (Phase 2)Study completedNCT04174716
What this trial is testing

Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)

Who this might be right for
Solid TumorsHomologous Recombination Repair Gene MutationHomologous Recombination Deficiency
Idience Co., Ltd. 108
Testing effectiveness (Phase 2)Active Not RecruitingNCT04030559
What this trial is testing

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Who this might be right for
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+14 more
Marc Dall'Era, MD 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT02286687
What this trial is testing

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Who this might be right for
Advanced Malignant NeoplasmATM Gene MutationBRCA1 Gene Mutation+5 more
M.D. Anderson Cancer Center 150
Testing effectiveness (Phase 2)Study completedNCT03025035
What this trial is testing

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Who this might be right for
Breast Cancer
Yuan Yuan 14
Large-scale testing (Phase 3)Active Not RecruitingNCT02655016
What this trial is testing

Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 733
Early research (Phase 1)Looking for participantsNCT06930755
What this trial is testing

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Nerviano Medical Sciences 24
Testing effectiveness (Phase 2)Looking for participantsNCT05568550
What this trial is testing

Pembro With Radiation With or Without Olaparib

Who this might be right for
Prostate Cancer
Zin W Myint 64
Not applicableLooking for participantsNCT06603506
What this trial is testing

Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

Who this might be right for
Endometrial Cancer
Centre Francois Baclesse 16
Not applicableLooking for participantsNCT06660147
What this trial is testing

Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

Who this might be right for
Ovarian Cancer
ARCAGY/ GINECO GROUP 327
Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Testing effectiveness (Phase 2)Ended earlyNCT04538378
What this trial is testing

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Who this might be right for
EGFR-Mutated Non-Small-Cell Lung CarcinomaSmall Cell/Neuroendocrine
National Cancer Institute (NCI) 4
Load More Results